A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This multiple-center, multiple-dose, randomized, double-blind, double-dummy,
placebo-controlled, positive-controlled, parallel group study will investigate the effect of
RO4917838 on the QTc interval in healthy volunteers. Healthy volunteers will be randomized to
one of 4 treatment arms; Arm A: low dose of RO4917838, Arm B: high dose of RO4917838, Arm C:
placebo to RO4917838 and moxifloxacin on Day 1, Arm D: placebo to RO4917838 and moxifloxacin
on Day 11. The anticipated time on study treatment is 11 days.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination